HAVANA TIMES, March 22 – Cuban scientists have carried out clinical tests of the CIMAvaxEGF product on 800 patients in Canada, Great Britain and Malaysia, reported IPS. The vaccine’s aim is to prolong the progression of tumors as long as possible. Studies on the medicine for lung cancer patients began in 1992.
The medicine reportedly has few side effects and exclusively attacks the cancerous cells without affecting the normal ones. Cuba currently produces 38 medicines which it markets in some 40 countries.